Veru reports qtrly loss per share $0.05

Veru reports higher net revenues for fiscal 2020 third quarter.q3 revenue $10.3 million versus refinitiv ibes estimate of $11 million.received agreement, positive input from fda on phase 3 trial design for veru-111; phase 3 trial expected to commence in q1 2021.qtrly loss per share $0.05.cash and cash equivalents were $15.4 million as of june 30.

VERU Ratings Summary

VERU Quant Ranking